IPO Listed — 15 Dec 2025

Listing Price: ₹1470 (+38.42% vs ₹1062)

View GMP History →

IPO Details GMP Review

More sections

Other pages for this IPO

Subscription Allotment

Corona Remedies IPO Review

Q: What does the score of 100 mean for Corona Remedies IPO?

The score of 100 is an aggregate of all analyst ratings tracked for Corona Remedies IPO. A score in this range indicates strong analyst confidence — most analysts are recommending a subscribe.

Q: What was the actual listing price of Corona Remedies IPO?

Corona Remedies IPO listed on December 15, 2025 at ₹1470, against the issue price of ₹1062 — a gain of +38.42% (₹408 per share).

Q: What is the price band and lot size of Corona Remedies IPO?

Corona Remedies IPO is priced at ₹₹1,008 – ₹1,062 per share. The minimum lot size is 14 shares. Subscription ran from 08 Dec 2025 to 10 Dec 2025.

Corona Remedies IPO has been reviewed by 15 analysts, and the overall consensus is Strong Apply — carrying a score of 100. Out of the 15 analysts who have covered this IPO, 15 recommend subscribing — reflecting a mixed view from the analyst community.

The issue is priced in the band of ₹₹1,008 – ₹1,062 per share , with a minimum application size of 14 shares . Subscription ran from 08 Dec 2025 to 10 Dec 2025. As of now, the grey market premium (GMP) for Corona Remedies IPO is quoting at ₹300 (484%), which gives a preliminary sense of how the street is pricing the listing — though GMP is unofficial and can swing sharply before the listing date. Scroll down for the full analyst breakdown and analyst-wise verdicts.

General Review

Corona Remedies is a pharmaceutical company whose revenue grew from ₹884 crore in FY23 to ₹1,196 crore in FY25, a 16.3 percent CAGR, with profit rising from ₹85 crore to ₹149 crore at 32 percent CAGR. Coverage was strongly positive: fifteen of the seventeen analysts said subscribe.

Listing Gains

At the ₹1,062 upper band the notes value the issue at about 35.3 to 43.5 times earnings, with EV to sales near 5.5 times. Analysts consider that acceptable given the profit growth on offer. With fifteen subscribe ratings and no avoid rating, the coverage pointed to a positive listing.

Short Term Strategy

Margins have expanded, with operating margin moving from 23.32 percent in FY25 to 24.29 percent in the June 2025 quarter, and EBITDA reaching ₹71.80 crore in that quarter against ₹245.91 crore for the full year. The issue is largely an offer for sale at ₹655.37 crore.

Long Term Strategy

The long-term case in the notes rests on consistent double-digit revenue growth with profit compounding faster, which points to operating leverage in the branded formulations model. With profit growing at roughly twice the rate of revenue over FY23 to FY25, sustaining that gap is what the subscribe ratings depend on.

Disclaimer: This review is an AI summary derived from the reviews of all analysts.

Analyst Verdict & Score
Detailed Review
Analyst Reviews
Frequently Asked Questions

Analyst Sentiment

Analytical Score

How it's calculated?

Strong Apply

100 / 100

Recommend Subscribe

Based on 15 analyst reviews

15 / 15

Higher consensus indicates broader analyst agreement.

Analyst Review

Analyst	Verdict	View
Nirmal Bang	Apply
Canara Bank Securities	Apply
Anand Rathi	Apply
BP Equities	Apply
GEPL Capital	Apply
Choice equity broking	Apply
SBI Securities	Apply
Sushil Finance	Apply
Lakshmishree Investment	Apply
Marwadi Shares & Finance	Apply
Ventura Securities	Apply
Capital Market	Apply
Swastika Investmart	Apply
Hem Securities	Apply
Stoxbox	Apply
Bajaj finance pvt ltd	Not rated
Dilip Davda	Not rated	-

Latest IPO Reviews

Manika Plastech Strong Apply

Score

Veegaland Developers Apply

Score

Rentomojo Apply

Score

Asset Reconstruction Co.(India) Strong Apply

Score

Frequently Asked Questions

Should I apply for Corona Remedies IPO?

Based on analyst coverage tracked on this page, the overall verdict for Corona Remedies IPO is Strong Apply. Out of 15 analysts who have reviewed this IPO, 15 recommend subscribing. Always cross-check with the full analyst reviews below and consult a SEBI-registered advisor before making any investment decision.

What does the score of 100 mean for Corona Remedies IPO?

The score of 100 is an aggregate of all analyst ratings tracked for Corona Remedies IPO. A score in this range indicates strong analyst confidence — most analysts are recommending a subscribe. Scroll down to read individual analyst verdicts for more context.

What was the actual listing price of Corona Remedies IPO?

Corona Remedies IPO listed on December 15, 2025 at ₹1470 , against the issue price of ₹1062 — a gain of +38.42% (₹408 per share). View the full GMP history page for day-wise pre-listing trends.

What is the price band and lot size of Corona Remedies IPO?

Corona Remedies IPO was priced at ₹₹1,008 – ₹1,062 per share. The minimum lot size is 14 shares. Subscription ran from 08 Dec 2025 to 10 Dec 2025.

Explore Corona Remedies IPO Further

Track every stage of this IPO:

📈

GMP Today

Live grey market premium

📊

Subscription Status

Real-time bidding data

📋

Allotment Status

Check if you got shares

Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.